Oral Drug Combo Shows Efficacy for Older AML Patients; Delayed Pegfilgrastim Reduces Breast Cancer Bone Pain
Jun 10, 2026
Two separate clinical trials have reported advances in cancer care. An oral drug combination of decitabine-cedazuridine and venetoclax showed efficacy in older patients with acute myeloid leukemia, with a 47% complete response rate in a phase 2b trial. A separate randomized controlled trial found that delaying pegfilgrastim administration to 72 hours post-chemotherapy significantly reduced bone pain in women with stage I–III breast cancer.